Jocelyn R. Farmer

Jocelyn R. Farmer

Auto-generated profile, based on publicly available information

Jocelyn R. Farmer

Clinical Immunodeficiency Program of Beth Israel Lahey Health, Division of Allergy and Immunology, Lahey Hospital & Medical Center, Burlington, MA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2018 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SBSara Barmettler
Sara Barmettler
MOMei-Sing Ong
Mei-Sing Ong
JFJocelyn R. Farmer
Jocelyn R. Farmer
HCHyon Choi
Hyon Choi
JWJolan Walter
Jolan Walter
Rituximab is an anti-CD20 chimeric monoclonal antibody that depletes CD20-expressing B cells. Rituximab is used in a broad range of conditions, including cancer, rheumatologic conditions, and primary immunodeficiency. Current US Food and Drug Administration–approved indications include non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.1 In addition, there are many off-label uses in other specialties2 and expanding indications for rituximab in common variable immunodeficiency (CVID)3 and ongoing combination therapy trials.4

1 October 2005 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Open access
PDF file
RHRichard C. Ho
Richard C. Ho
MHMichael F. Hirshman
Michael F. Hirshman
YLYangfeng Li
Yangfeng Li
DCDongsheng Cai
Dongsheng Cai
JFJocelyn R. Farmer
Jocelyn R. Farmer
LGLaurie J. Goodyear
Laurie J. Goodyear
Nuclear factor-κB (NF-κB) is a transcription factor with important roles in regulating innate immune and inflammatory responses. NF-κB is activated through the phosphorylation of its inhibitor, IκB, by the IκB kinase (IKK) complex. Physical exercise elicits changes in skeletal muscle gene expression, yet signaling cascades and transcription factors involved remain largely unknown. To determine whether NF-κB signaling is regulated by exercise in vivo, rats were run on a motorized treadmill for 5–60 min. Exercise resulted in up to twofold increases in IKKα/β phosphorylation in the soleus and red gastrocnemius muscles throughout the time course studied. In red gastrocnemius muscles, NF-κB activity increased 50% 1–3 h after 60 min of treadmill exercise, returning to baseline by 5 h. Contraction of isolated extensor digitorum longus muscles in vitro increased IKKα/β phosphorylation sevenfold and this was accompanied by a parallel increase in IκBα phosphorylation. Additional kinases that are activated by exercise include p38, extracellular-signal regulated protein kinase (ERK), and AMP-activated protein kinase (AMPK). Inhibitors of p38 (SB-203580) and ERK (U-0126) blunted contraction-mediated IKK phosphorylation by 39 ± 4% ( P = 0.06) and 35 ± 10% ( P = 0.09), respectively, and in combination by 76 ± 5% ( P < 0.05), suggesting that these kinases might influence the activation of IKK and NF-κB during exercise. In contrast, 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside, an activator of AMPK, had no effect on either IKK or NF-κB activity. In conclusion, acute submaximal exercise transiently stimulates NF-κB signaling in skeletal muscle. This activation is a local event because it can occur in the absence of exercise-derived systemic factors.

9 January 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
JFJocelyn R. Farmer
Jocelyn R. Farmer
MOMei-Sing Ong
Mei-Sing Ong
SBSara Barmettler
Sara Barmettler
LYLael M. Yonker
Lael M. Yonker
RFRamsay Fuleihan
Ramsay Fuleihan
JWJolan E. Walter
Jolan E. Walter
Common variable immunodeficiency (CVID) is increasingly recognized for its association with autoimmune and inflammatory complications. Despite recent advances in immunophenotypic and genetic discovery, clinical care of CVID remains limited by our inability to accurately model risk for non-infectious disease development. Herein, we demonstrate the utility of unbiased network clustering as a novel method to analyze inter-relationships between non-infectious disease outcomes in CVID using databases at the USIDNET, the centralized immunodeficiency registry of the United States, and Partners, a tertiary care network in Boston, MA with a shared electronic medical record amenable to natural language processing. Immunophenotypes were comparable in terms of native antibody deficiencies, low titer response to pneumococcus, and B cell maturation arrest. However, recorded non-infectious disease outcomes were more substantial in the Partners cohort across the spectrum of lymphoproliferation, cytopenias, autoimmunity, atopy, and malignancy. Using unbiased network clustering to analyze 34 non-infectious disease outcomes in the Partners cohort, we further identified unique patterns of lymphoproliferative (two clusters), autoimmune (two clusters), and atopic (one cluster) disease that were defined as CVID non-infectious endotypes according to discrete and non-overlapping immunophenotypes. Markers were both previously described (high serum IgE in the atopic cluster (OR 6.5) and low class-switched memory B cells in the total lymphoproliferative cluster (OR 9.2)) and novel (low serum C3 in the total lymphoproliferative cluster (OR 5.1)). Mortality risk in the Partners cohort was significantly associated with individual non-infectious disease outcomes as well as lymphoproliferative cluster 2, specifically (OR 5.9). In contrast, unbiased network clustering failed to associate known comorbidities in the adult USIDNET cohort. Together these data suggest that unbiased network clustering can be used in CVID to redefine non-infectious disease inter-relationships, however, applicability may be limited to datasets well-annotated through mechanisms such as natural language processing. The lymphoproliferative, autoimmune, and atopic Partners CVID endotypes herein described can be used moving forward to streamline genetic and biomarker discovery and to facilitate early screening and intervention in CVID patients at highest risk for autoimmune and inflammatory progression.

1 July 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
JFJocelyn R. Farmer
Jocelyn R. Farmer
ZFZsofia Foldvari
Zsofia Foldvari
BUBoglarka Ujhazi
Boglarka Ujhazi
SRSuk See De Ravin
Suk See De Ravin
KCKarin Chen
Karin Chen
JWJolan E Walter
Jolan E Walter
Although autoimmunity and hyperinflammation secondary to recombination activating gene (RAG) deficiency have been associated with delayed diagnosis and even death, our current understanding is limited primarily to small case series. Understand the frequency, severity, and treatment responsiveness of autoimmunity and hyperinflammation in RAG deficiency. In reviewing the literature and our own database, we identified 85 patients with RAG deficiency, reported between 2001 and 2016, and compiled the largest case series to date of 63 patients with prominent autoimmune and/or hyperinflammatory pathology. Diagnosis of RAG deficiency was delayed a median of 5 years from the first clinical signs of immune dysregulation. Most patients (55.6%) presented with more than 1 autoimmune or hyperinflammatory complication, with the most common etiologies being cytopenias (84.1%), granulomas (23.8%), and inflammatory skin disorders (19.0%). Infections, including live viral vaccinations, closely preceded the onset of autoimmunity in 28.6% of cases. Autoimmune cytopenias had early onset (median, 1.9, 2.1, and 2.6 years for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively) and were refractory to intravenous immunoglobulin, steroids, and rituximab in most cases (64.7%, 73.7%, and 71.4% for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively). Evans syndrome specifically was associated with lack of response to first-line therapy. Treatment-refractory autoimmunity/hyperinflammation prompted hematopoietic stem cell transplantation in 20 patients. Autoimmunity/hyperinflammation can be a presenting sign of RAG deficiency and should prompt further evaluation. Multilineage cytopenias are often refractory to immunosuppressive treatment and may require hematopoietic cell transplantation for definitive management.

15 June 2010 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DPDaniel C. Peltier
Daniel C. Peltier
ASAllison Simms
Allison Simms
JFJocelyn R. Farmer
Jocelyn R. Farmer
DMDavid J. Miller
David J. Miller
Innate immune pathways are early defense responses important for the immediate control and eventual clearance of many pathogens, where signaling is initiated via pattern recognition receptor (PRR)-mediated events that occur in a ligand- and cell-type specific manner. Within CNS neurons, innate immune pathways are likely crucial to control pathogens that target these essential yet virtually irreplaceable cells. However, relatively little is known about the induction and regulation of neuronal PRR signaling. In this report, we used human neuronal cell lines and primary rat neuronal cultures to examine PRR expression and function. We found that several innate immune receptor ligands, including Sendai virus, the dsRNA mimetic polyinosinic-polycytidylic acid, and LPS all activated differentiation-dependent neuronal innate immune pathways. Functional genetic analyses revealed that IFN regulatory factor 3-mediated pathways that resulted in IFN-β transcriptional upregulation were activated in cultured human neuronal cells by the PRRs TLR3, MDA5, or RIG-I in a ligand-specific manner. Furthermore, genome-wide transcriptional array and targeted genetic and pharmacologic analyses identified PI3K signaling as crucial for the induction of innate immune pathways in neurons. These results indicate that human neuronal cells possess specific and functional PRR pathways essential for the effective induction of innate immune responses, and suggest that neurons can play an active role in defense against neurotropic pathogens.

1 November 2016 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Open access
JWJolan E Walter
Jolan E Walter
JFJocelyn R. Farmer
Jocelyn R. Farmer
ZFZsofia Foldvari
Zsofia Foldvari
TTTroy R. Torgerson
Troy R. Torgerson
MCMegan A. Cooper
Megan A. Cooper
A broad spectrum of autoimmunity is now well described in patients with primary immunodeficiencies (PIDs). Management of autoimmune disease in the background of PID is particularly challenging given the seemingly discordant goals of immune support and immune suppression. Our growing ability to define the molecular underpinnings of immune dysregulation has facilitated novel targeted therapeutics. This review focuses on mechanism-based treatment strategies for the most common autoimmune and inflammatory complications of PID including autoimmune cytopenias, rheumatologic disease, and gastrointestinal disease. We aim to provide guidance regarding the rational use of these agents in the complex PID patient population.